Class Ia PI3K pan-inhibitors PX-866 and BKM120 (buparlisib) have shown good anti-tumor effects in preclinical studies of a variety of tumors (126, 134) and some clinical trials in CRC patients are ongoing. Here, PIK3CA is linked to neoplasm.